<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81593">
  <stage>Registered</stage>
  <submitdate>19/09/2006</submitdate>
  <approvaldate>19/09/2006</approvaldate>
  <actrnumber>ACTRN12606000410550</actrnumber>
  <trial_identification>
    <studytitle>Investigation of AV411 in Healthy Subjects</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Center Trial to Assess the Safety, Tolerability, and Pharmacokinetics of AV411 in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Healthy subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose oral AV411 (30 mg) on Study day 1
Oral AV411 (30 mg) twice daily for 14 days beginning on Study day 3</interventions>
    <comparator>Placebo on Study day 1
Placebo twice daily for 14 days beginning on Study day 3</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of AV411 at a single dose level in healthy subjects</outcome>
      <timepoint>Daily</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma collection for pharmacokinetic sampling</outcome>
      <timepoint>On Study days 2, 3, 5, 10, 13,  17 and 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Full pharmacokinetic analysis</outcome>
      <timepoint>On Study days 1, 6 and 16.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine collection for metabolite analyses</outcome>
      <timepoint>On Study days 1, 6, 16 and 20.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Nonsmoking.-No clinical abnormality in laboratory and urine analyses.-Normal renal function Glomerular Filtration Rate (GFR) &gt;90 mL/min.-Liver enzymes less than twice the upper limit of normal.-Electrocardiogram within normal limits at screening.-Willing to use barrier contraceptive during the period of the study.-Negative pregnancy test on Study Day 1 for female subjects of child-bearing potential.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to Pinatos or its components.-Conditions which might affect drug absorption, metabolism or excretion.-Untreated mental illness, current drug addiction or abuse or alcoholism.-Donated blood in the past 90 days or have poor peripheral venous access.-Platelets &lt;100,000 per mm3 or a history of thrombocytopenia.-Confirmed diagnosis of chronic liver disease.-Positive for HIV.-Female subjects who are pregnant or nursing mothers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Off-site holder of allocation</concealment>
    <sequence>Block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Pharmacist is unblinded. Subject and and all other study personnel are blinded</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>5/10/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avigen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Avigen, Inc.</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tamara Murdock</name>
      <address>CMAX (A Division of IDT Australia LTD)
Royal Adelaide Hospital
Level 5 East Wing
North Terrace Adelaide SA 5000</address>
      <phone>+61 8 84163144</phone>
      <fax>+61 8 83618615</fax>
      <email>tamara.murdock@cmax.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Charlotte Goess</name>
      <address>CMAX (A Division of IDT Australia LTD)
Royal Adelaide Hospital
Level 5 East Wing
North Terrace Adelaide SA 5000</address>
      <phone>+61 8 84163100</phone>
      <fax>+61 8 83618615</fax>
      <email>charlotte.goess@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>